VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
18 mai 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
12 mai 2022 16h05 HE
|
VYNE Therapeutics Inc.
Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to...
VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
10 mai 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th
06 mai 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
07 avr. 2022 08h00 HE
|
VYNE Therapeutics Inc.
At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehiclePhase 2a safety and efficacy results expected in the second...
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
30 mars 2022 08h00 HE
|
VYNE Therapeutics Inc.
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated numerically superior results at 1mg/kg and...
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
17 mars 2022 08h00 HE
|
VYNE Therapeutics Inc.
FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and validated inflammation models BRIDGEWATER,...
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo
07 mars 2022 07h00 HE
|
VYNE Therapeutics Inc.
VYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflammatory biomarkers involved in the pathogenesis of vitiligo, an immune-modulated skin...
VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
03 mars 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
19 janv. 2022 08h00 HE
|
VYNE Therapeutics Inc.
Systemic bioavailability of JAK inhibitor (tofacitinib) and S1P receptor modulator (fingolimod) in topical formulation substantially lower compared to oral equivalents Mean Cmax of tofacitinib...